Synthesis and antibacterial activity of 2-phenyl-5-aryl-4, 5, 6, 7, 8, 9-hexahydro-1,2.4-triazolo[1,5-A]quinazolines by Nazeer, Areesha et al.
AfinidAd LXX, 563, Julio - Septiembre 2013220
RESUMEN
Se ha desarrollado un método para la síntesis de 2-fenil-
5-aril-4, 5, 6, 7, 8, 9 - hexahydrotriazolo [1,5-a] quinazoli-
nas. El 3-amino-5-fenil-1,2,4-triazol forma bases de Schiff 
con aldehídos aromáticos que en el tratamiento con ci-
clohexanona en presencia de ácido acético glacial y cloru-
ro de cinc anhidro se cicla para producir los compuestos 
del título. Las estructuras de los compuestos sintetizados 
fueron determinadas mediante técnicas espectroscópicas 
(FTIR y 1H-RMN) y análisis elemental. La actividad anti-
bacteriana de los compuestos también se examinó frente 
a cuatro cepas bacterianas diferentes por el método de 
disco de placa de agar. 
Palabras clave: Reacción Doebner-Miller, triazoles, bases 
de Schiff, espectros de RMN, espectros de masas.
SUMMARY
A method for the synthesis of 2-phenyl-5-aryl-4, 5, 6, 7, 8, 
9- hexahydrotriazolo[1,5-a] quinazolines was developed. 
3-Amino-5-phenyl-1,2,4-triazole formed  Schiff’s bases 
with aromatic aldehydes which on treatment  with cy-
clohexanone in the presence of glacial acetic acid and an-
hydrous zinc chloride cyclized to produce title compounds. 
The structures of synthesized compounds were elucidated 
by spectroscopic techniques (FTIR and 1H-NMR) and ele-
mental analysis. The compounds were also screened for 
their antibacterial activities against four different bacterial 
strains by agar plate disc method. 
Key words: Doebner-Miller Reaction, Triazoles, Schiff’s 
bases, NMR Spectra, Mass Spectra.
RESUM
S’ha desenvolupat un mètode per a la síntesi de 2-fenil-5-
aril-4, 5, 6, 7, 8, 9 - hexahydrotriazolo [1,5-a] quinazolines. 
El 3-amino-5-fenil-1,2,4-triazole forma bases de Schiff 
amb aldehids aromàtics, els quals al ser tractats amb ci-
clohexanona en presència d’àcid acètic glacial i clorur de 
zinc anhidre es cicla per produir els compostos del títol. 
Les estructures dels compostos sintetitzats van ser deter-
minades mitjançant tècniques espectroscòpiques (FTIR i 
1H-RMN) i anàlisi elemental. L’activitat antibacteriana dels 
compostos també es va examinar contra quatre soques 
bacterianes diferents pel mètode de disc de placa d’agar.
Paraules clau: Reacció Doebner-Miller, triazols, bases de 
Schiff, espectres de RMN, espectres de masses.
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INTRODUCTION
Triazole derivatives show a variety of pharmacological, fun-
gicidal, herbicidal and insecticidal activities (1-7). 1,2,4-Tria-
zoles belong to a new class of antimicrobial agents, fluco-
nazole (I) and itraconazole are being used as antimicrobial 
drugs (8,9). It has also been reported that biheterocyclic 
compounds containing 1,2,4-triazole ring are good anti-
microbial agents(10-13), The generally known systems fused 
to triazoles are pyridines, pyridazines, quinazolines, pyra-
zines and triazines(14-17). 
Quinazolines and condensed quinazolines on the other 
hand also possess diverse pharmacological activities and 
they are used as potent tyrosine kinase inhibitors (18, 19). 
Triazoloquinazolines constitute an important class of phar-
maceutically important compounds(20-22). More recently re-
ported 1,2,4-triazoloquinazolines (II) exhibited antihistami-
nic activity(23, 24).A 1,2,3-triazolo[1,5-a]quinazoline was first 
reported 36 years ago by Tennant; anthranilic acid was 
used as the starting material for this synthesis. Anthranilic 
acid was converted into 2-azidobenzoic acid by diazotisa-
tion followed by reaction with the isoxazole acetonitrile to 
give the final product(25). 
5,6,7,8-Tetrahydro-4H-spiro{[1,2,3]triazolo[5,1-b]quinazo-
line-9,1’-cyclohexane}-3-carboxamide (III) was prepared 
by the reaction of 4-amino-5-carboxamido-1,2,3-triazole 
with cyclohexanone in dry ethanol for three hours. The 
yield of the reaction was improved by carrying out this re-
action under microwave irradiation for 20 minutes at 120°C 
using methanol solvent(26). A condensation of 3-substituted 
5-amino-1,2,4-triazoles with 2-cyclohexylidenecyclohexa-
none in DMF resulted in the synthesis of 2′-substituted 
5′,6′,7′,8′-tetrahydro-4′H-spiro[cyclohexane-1,9′-[1,2,4]
triazolo[5,1-b]quinazolines] which were hydrogen-
ted by using sodium borohydride in ethanol to give 
2′-substituted cis-4a’,5′,6′,7′,8′,8a’-hexahydro-4′H-
spiro[cyclohexane-1,9′-[1,2,4]triazolo[5,1-b]quinazolines]
(27). 
A general method for the synthesis of triazoloquinazo-
lines involves the reaction of hydrazinoquinazolines with 
aliphatic carboxylic acid or their esters(28-31). 3-Phenyl-
s-triazolo[4,3-c]quinazoline was prepared by heating 
4-(3-phenyltetrazolyl)quinazoline(32). 
The mechanism for the synthesis of benzopyrimidine he-
terocycle has been  studied. The heterocyclization reac-
tion of 3-amino-1,2,4-triazole with arylidene derivatives 
of dimedone  resulted in the synthesis of  9-aryl-6,6-di-
methyl-5,6,7,9-tetrahydro-1,2,4-triazolo[5,1-b]quinazolin-
8-ones(33). 
In view of the above findings, we have synthesized some 
novel derivatives of triazolo[1,5-a]quinazoline (2a-g) 
(Scheme 1) via the Schiff’s bases from 3-amino-5-phenyl-
1,2,4-triazole and are reported in this paper. The synthe-
sized compounds were also tested for their antibacterial 
activities.
MATERIALS AND METHODS
All the chemicals used in this synthesis were of analytical 
grade and were mostly used without further purification. 
The starting material 3-amino-5-phenyl-1,2,4-triazole was 
obtained commercially. Melting points were determined on 
a Gallenkamp melting point apparatus. Infrared spectro-
meter Shimadzu-408 was used for measuring the spectra 
in KBr disks. Proton magnetic resonance (PMR) spectra 
were taken on a Brucher 300 and 500 MHz spectrome-
ter. Elemental analysis were determined on a Perkin-Elmer 
model 240. Mass spectra were recorded on a Finnigan 
MAT 112. 
Synthesis of Schiff base (1a-g)(34).
3-(Benzylidene)-5-phenyl-1,2,4-triazole (1a)
General Method: Equimolar quantities of 3-amino-
5-phenyl-1,2,4-triazole (1.60 g; 0.01 mole) benzaldehyde 
(1.06g; 0.01 mole) and aluminium chloride (0.1g) were dis-
solved in absolute ethanol (10mL). It was refluxed for two 
hours on a water bath with occasional shaking. On cooling 
at room temperature white precipitates obtained  were fil-
tered, dried and recrystallized from ethanol
m.p. 190°C; Yield: 70 %
Compounds 1b-1g were prepared from 3-amino-5-phen-
yl-1,2,4-triazole and the corresponding aldehydes by the 
above general method.   
3-(o-nitrobenzylidene)-5-phenyl-1,2,4-triazole (1b): 
m.p. 145°C ; Yield: 72%
3-(o-methoxybenzylidene)-5-phenyl-1,2,4-triazole (1c): 
m.p. 170°C ; Yield: 68%
3-(o-bromobenzylidene)-5-phenyl-1,2,4-triazole (1d): 
m.p. 160°C ; Yield: 60%
3-(o-chlorobenzylidene)-5-phenyl-1,2,4-triazole (1e): 
m.p. 155°C ; Yield: 73%
3-(2,4-dichlorobenzylidene)-5-phenyl-1,2,4-triazole 
(1f): m.p. 160°C ; Yield: 76%
Anthranilic acid was converted into 2-azidobenzoic acid by diazotisation followed by 
reaction with the isoxazole ac tonitrile to give the final product(25).  
5,6,7,8-Tetrahydro-4H-spiro{[1,2,3]triazolo[5,1-b]quinazoline-9,1'-cyclohexane}-3-
carb xamide (III) was prepared by the reactio  of 4-amino-5-carboxamido-1,2,3-triazole 
with cyclohexanone in dry ethanol for three hours. The yield of the reaction was improved by 
carrying out this reaction under microwave irradiation for 20 minutes at 120°C using 
methanol solvent(26). A condensation of 3-substituted 5-amino-1,2,4-triazoles with 2-
cyclohexylidenecyclohexanone in DMF resulted in the synthesis of 2′-Substituted 5′,6′,7′,8′-
tetrahydro-4′H-spiro[cyclohexane-1,9′-[1,2,4]triazolo[5,1-b]quinazolines] which were 
hydrogented by using sodium borohydride in ethanol to give 2′-substituted cis-
4a',5′,6′,7′,8′,8a'-hexahydro-4′H-spiro[cyclohexane-1,9′-[1,2,4]triazolo[5,1-
b]quinazolines](27).  
A general method for the synthesis of triaz loqui azolin s involves the reaction of 
hydrazinoquinazolines with aliphatic carboxylic acid or their esters(28-31). 3-Phenyl-s-
triazolo[4,3-c]quinazoline was prepared by heating 4-(3-pheny tetrazolyl)quinazoline(32).  
The mechanism for the synthesis of benzopyrimidine heterocycle has been  studied. The 
heterocyclization reaction of ami o-1,2,4-triazole with aryli ene derivatives of dimedone  
resulted in the synthesis of  9-aryl-6,6-dimethyl-5,6,7,9-tetrahydro-1,2,4-triazolo[5,1-
b]quinazolin-8-ones(33).  
In view of the above findings, we have synthesized some novel derivatives of triazolo[1,5-a] 
quinazoline (2a-g) (Scheme 1) via the Schiff’s bases from 3-amino-5-phenyl-1,2,4-triazole 
and are reported in this paper. The synthesized compounds were also tested for their 
antibacterial activities. 
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3-(o-hydroxybenzylidene)-5-phenyl-1,2,4-triazole (1g): 
m.p. 130°C ; Yield: 76%
Synthesis of 2-phenyl-5-aryl-4, 5, 6, 7, 8, 9- hexahydro-
1,2,4-triazolo[1,5-a]quinazolines (2a-g).  
 4, 5, 6, 7, 8, 9- Hexahydro-2,5-diphenyl-1,2,4-
triazolo[1,5-a]quinazoline (2a)
General Method: A mixture of schiff base [1a], (2.48g, 
0.01 mole), cyclohexanone (0.98g, 0.01 mole) and anhy-
drous zinc chloride (1.0g) was refluxed in glacial acetic 
acid (10mL) for six hours. On cooling the reaction mixtu-
re was poured over crushed ice with continuous stirring 
and allowed to stand for thirty minutes. The solid product 
which separated out was filtered, washed with excess of 
water, dried and recrystallized from ethanol to give the de-
sired cyclic product. 
m.p. 190°C; Yield: 68%
IR (KBr) cm-1: 3300, 3050 (NH), 2850, 1700, 1650 (C=N), 
1590 (C=C), 650. 
1H-NMR (DMSO d6) δ: 1.80 (8H, m, 4×CH2), 2.30 (1H, s, 
H-5), 7.30-9.30 (10H, m, Ar-H), 9.32 (1H, s, NH). 
CHN: C21H20N4, Calculated: C: 77.30, H: 5.52, N: 17.28 %. 
Found: C:77.34, H: 5.50, N: 17.15 %.
4, 5, 6, 7, 8, 9- Hexahydro-5-o-nitrophenyl-2-phenyl-
1,2,4-triazolo[1,5-a]quinazoline (2b): 
m.p. 130°C; Yield: 79%
IR (KBr) cm-1: 3150 (NH), 1702, 1590 (C=C),1520, 1340 
(NO2). 
1H-NMR (DMSO d6) δ: 1.68 (8H, m, 4×CH2), 2.30 (1H, s, 
H-5), 6.83-8.42 (10H, m, Ar-H), 9.50 (1H, s, NH). 
CHN: C21H19N5O2, Calculated: C: 67.92, H: 4.58, N: 18.87 
%. Found: C:67.96, H: 4.55, N: 18.85 %
6, 7, 8, 9- Tetrahydro-5-o-methoxyphenyl-2-phenyl-
1,2,4-triazolo[1,5-a]quinazoline (2c): 
m.p. 180°C; Yield: 68%
IR (KBr) cm-1: 2835 (OCH3), 1720, 1635, 1550 (C=N), 1410.
1H-NMR (CHCl3)δ: 1.80 (8H, m, 4×CH2), 2.55 (3H, m, 
OCH3), 7.30-7.85 (10H, m, Ar-H).
CHN: C22H20N4O, Calculated: C: 74.16, H: 5.62, N: 15.73 
%. Found: C:74.13, H: 5.60, N: 15.75 %
MS: m/z (%) = C22H20N4O [M
+]: 366
4, 5, 6, 7, 8, 9- Hexahydro-5-o-bromophenyl-2-phenyl-
1,2,4-triazolo[1,5-a]quinazoline (2d): 
m.p. 170°C; Yield: 65%
IR (KBr) cm-1: 3200, 3100 (NH), 1580 (C=C), 1210, 1140.
1H-NMR (DMSO d6) δ: 1.72 (8H, m, 4×CH2), 2.22 (1H, s, 
H-5), 6.83-8.00 (10H, m, Ar-H), 9.30 (1H, s, NH). 
CHN: C21H19N4Br, Calculated: C: 62.22, H: 4.20, N: 13.83, 
Br: 19.75 %. Found: C:62.25, H: 4.23, N: 13.80, Br: 19.75 
%.
4, 5, 6, 7, 8, 9- Hexahydro-5-o-chlorophenyl-2-phenyl-
1,2,4-triazolo[1,5-a]quinazoline (2e): 
m.p. 152°C; Yield: 80%
IR (KBr) cm-1: 3100, 1670 (C=N), 1600  (C=C), 1470, 1260.
1H-NMR (CHCl3) δ: 1.84 (8H, m, 4×CH2), 2.43 (1H, s, H-5), 
6.43-7.76 (10H, m, Ar-H), 9.45 (1H, s, NH). 
CHN: C21H19N4Cl, Calculated: C: 69.90, H: 4.72, N: 15.53, 
Cl: 9.85 %. Found: C:69.94, H: 4.69, N: 15.50, Cl: 9.85 %.
4, 5, 6, 7, 8, 9- Hexahydro-5-(2,4-dichlorophenyl)-
2-phenyl-1,2,4-triazolo[1,5-a]quinazoline (2f): 
m.p. 170°C; Yield: 79%
IR (KBr) cm-1: 3250, 3100,  2990, 1580 (C=C), 1455, 1325.
1H-NMR (DMSO d6) δ: 1.72 (8H, m, 4×CH2), 2.18 (1H, s, 
H-5), 6.80-7.92 (10H, m, Ar-H), 9.28 (1H, s, NH). 
(Scheme 1)
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RESULTS AND DISCUSSION  
3-Amino-5-phenyl-1,2,4-triazole was used as a starting material for the preparation of 2-
phenyl-5-aryl-4, 5, 6, 7, 8, 9- hexahydro-1,2,4-triazolo [1,5-a] quinazolines (2a-g) (Scheme 
1). As triazole derivatives and quinazolines have been reported to possess diverse 
pharmacological activities, so this 1,2,4-triazolo[1,5-a]quinazoline system was prepared 
keeping in view the biological importance of both the ring systems.  
3-Amino-5-phenyl-1,2,4-triazole condensed with aromatic aldehydes in absolute ethanol by 
using  AlCl3 as catalyst to give the respective Schiff bases (1a-g) which have already been
reported previously(34) These  Schiff bases with cyclohexanone in the presence of zin chloride 
and glacial acetic acid  cyclized to produce the corresponding 2-phenyl-5-aryl-4, 5, 6, 7, 8, 9- 
hexahydro-1,2,4-triazolo[1,5-a]quinazolines (2a-g) (Scheme-1). Glacial acetic acid has 
proved to be a good reaction medium, as it acts both as a solvent and as an acid co-catalyst 
together with anhydrous zinc chloride for this cyclization reaction with cyclohexanone. Using 
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CHN: C21H18N4Cl2, Calculated: C: 63.80, H: 4.05, N: 14.18, 
Cl: 17.97 %. Found: C:63.83, H: 4.02, N: 14.20, Cl: 17.97 
%.
4, 5, 6, 7, 8, 9- Hexahydro-5-o-hydroxyphenyl-2-phenyl-
1,2,4-triazolo[1,5-a]quinazoline (2g): 
m.p. 190°C; Yield: 78%
IR (KBr) cm-1: 3120, 2840, 1690 (OH), 1595 (C=C), 645. 
1H-NMR (DMSO d6) δ: 1.5-3.50 (8H, m, 4×CH2), 4.22 (1H, 
s, OH), 4.29 (1H, s, H-5), 6.80-8.40 (10H, m, Ar-H), 8.37 
(1H, s, NH). 
CHN: C21H20N4O, Calculated: C: 73.86, H: 5.62, N: 16.38 
%. Found: C:73.40, H: 6.02, N: 16.18 %.
MS: m/z (%) = C21H20N4O [M
+]: 344 
RESULTS AND DISCUSSION 
3-Amino-5-phenyl-1,2,4-triazole was used as a starting 
material for the preparation of 2-phenyl-5-aryl-4, 5, 6, 7, 
8, 9- hexahydro-1,2,4-triazolo [1,5-a] quinazolines (2a-g) 
(Scheme 1). As triazole derivatives and quinazolines have 
been reported to possess diverse pharmacological acti-
vities, so this 1,2,4-triazolo[1,5-a]quinazoline system was 
prepared keeping in view the biological importance of both 
the ring systems. 
3-Amino-5-phenyl-1,2,4-triazole condensed with aroma-
tic aldehydes in absolute ethanol by using  AlCl3 as ca-
talyst to give the respective Schiff bases (1a-g) which 
have already been reported previously(34). These  Schiff 
bases with cyclohexanone in the presence of zin chloride 
and glacial acetic acid  cyclized to produce the corres-
ponding 2-phenyl-5-aryl-4, 5, 6, 7, 8, 9- hexahydro-1,2,4-
triazolo[1,5-a]quinazolines (2a-g) (Scheme-1). Glacial 
acetic acid has proved to be a good reaction medium, as 
it acts both as a solvent and as an acid co-catalyst to-
gether with anhydrous zinc chloride for this cyclization re-
action with cyclohexanone. Using diverse benzaldehydes, 
corresponding products 2a-2g were obtained in good to 
excellent yields (65-80 %). 
The reaction was monitored through the melting points, 
TLC and IR data of the products.  Normally in this type of 
condensation/cyclization reactions (Doebner-Miller Reac-
tion(35)), the intermediate dihydro product often undergoes 
dehydration to furnish a fully aromatic ring. Here it seems 
that except 2c the other products were not oxidized un-
der these reaction conditions. The formation of hexahy-
dro-1,2,4-triazolo[1,5-a]quinazolines (2a-2b, 2d-2g) was 
confirmed by IR, 1H-NMR, MS and satisfactory elemental 
analysis data. 
The IR data of (2a) showed a strong absorption at 3100 
cm-1 indicated the presence of NH group confirmed the 
synthesis of non-aromatized product. Similarly the other 
characteristic absorptions were observed due to the pre-
sence of different substituents. In (2b) the presence of NO2 
group is indicated by the absorption bands at 1520 and 
1340   cm-1. In (2c) and (2g) the presence of OCH3and 
OH were indicated by the strong absorptions at 2835 and 
1690 cm-1 respectively. In (2c) the absence of absorption 
due to NH above 3100 cm-1 confirmed the formation of 
tetrahydro-1,2,4-triazolo[1,5-a]quinazoline.  
The 1H-NMR data of compounds (2b-g) showed a singlet 
at δ 2.30 due to aliphatic proton (H-5). A multiplet centred 
at δ 2.50 due to aliphatic protons (4×CH2) and NH pro-
ton  appeared at δ 9.32 as a singlet. A multiplet centred 
at δ 8.30 is assigned to aromatic protons. The PMR data 
of compound (2b) shows signals for aromatic protons as 
multiplet centred at δ 7.57. Another multiplet at δ 2.65 is 
observed due to three methoxy protons. A singlet at δ 2.12 
due to an aliphatic proton (H-5) and a multiplet centred at 
δ 1.80 due to CH2 (aliphatic) protons. Another singlet dis-
played at δ 9.30 is due to NH proton. The PMR data of (2g) 
shows characteristic signals of aromatic protons centred 
at δ 7.50 as multiplets. At δ 4.22 a singlet is observed for 
OH. Another multiplet showing signals at δ 1.5-3.50 are 
due to CH2 protons of quinazoline. 
Satisfactory elemental analysis and mass spectral data 
correspond to a particular molecular ion peak of all the 
cyclized products confirmed the formation of triazolo [1,5-
a] quinazoline (2a-g). Mass spectra of (2c) showed mo-
lecular ion peak m/z 356 according to molecular formula 
C22H20N4O. Mass spectrum of (2g) revealed a molecular 
ion peak at m/z 344 as expected, a hexahydro product, 
having molecular formula  C21H20N4O. The mass fragmen-
tation pattern (Scheme 2) showed a peak at m/z 251 co-
rresponds to the loss of C6H4OH (m/z 93) from the parent 
molecular ion peak. After this a base peak is obtained at 
m/z 185 due to loss of C4H4 (m/z 52) and CH2 (m/z 14). 
Further loss of C2H4 (m/z 26), N2 (m/z 28) and 2CN (m/z  26 
× 2=52) simultaneously, created a shorter fragment, co-
rresponding  to C6H5 (m/z 77). 
Antibacterial activity
Antibacterial activity of hexahydro-1,2,4-triazolo[1,5-a]
quinazolines (2a-g) was tested by Agar plate disc diffu-
sion method(36) against six different bacterial strains; Sta-
phylococcus aureus (gram +ve), Pseudomonas (gram –ve), 
Escherichia coli (gram –ve) and Klebsiella (gram –ve). The 
filter paper disc (6.00 mm in diameter) was soaked with the 
solution of 50 mg of compound in 1 mL of chloroform was 
placed in the centre of plate. The plates were incubated 
with the growing cultures of bacterial strains. 
The four different types of bacterial cultures were inocu-
lated and were further incubated at 37°C for 24-48 hours. 
Vibramycin and Cefizox were used as standards. The test 
organism S.aureus and E. coli showed an inhibition zone of 
(30 mm) for Vibramycin while Pseudomonas showed resis-
tance. Klebsiella showed an inhibition zone of (10 mm) for 
Vibramycin and (20 mm) for Cefizox, while in case of Cefi-
zox no antibacterial activity was observed in S. aureus and 
E. coli but klebsiella showed an inhibition zone of 20 mm. 
In case of antibacterial activity of synthesized compounds 
(2a-g), only two compounds 2c and 2g  showed moderate 
activity against S.aureus, Klebsiella, Pseudomonas and E. 
coli. The results of antibacterial activity are given in Ta-
ble-1. 
Table 1. Antibacterial Activity of 1,2,4-tri-
azolo [1,5-a] quinazolines 2a-2g
Compound No. S.aureus Klebsiella Pseudomonas E. coli
2a - - - -
2b - - - -
2c - 20 - 17
2d - - - -
2e - - - -
2f - - - -
2g 25 - 20 12
VIB 30 10 - 30
CEF - 20 - -
VIB: Vibramycin, CEF: Cefizox
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CONCLUSIONS
The method used for the synthesis of 1,2,4-triazolo[1,5-a]
quinazolines is a mild and efficient one as it gives better 
yields (65-80%). Schiff’s bases being the reactive inter-
mediate, their preformation or in situ formation both gave 
satisfactory results. The synthesized compounds showed 
moderate activity against some bacterial strains.  
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